Barclays Maintains Equal-Weight on Chemours, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Michael Leithead has maintained an Equal-Weight rating on Chemours (NYSE:CC) and raised the price target from $38 to $40.
July 11, 2023 | 10:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has maintained an Equal-Weight rating on Chemours and raised the price target from $38 to $40, which could potentially influence the stock's performance.
The price target for Chemours has been raised by Barclays, which indicates a positive outlook for the stock. This could potentially lead to an increase in the stock's price as investors may interpret this as a sign of the company's strong future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100